Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Papillomavirus Infections 2Leiomyoma 2Inflammation 2Frailty 2Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Radiodermatitis 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Atypical Squamous Cells of the Cervix 1

Interventions

Oxaliplatin 27Fluorouracil 23Cetuximab 23Leucovorin 22Bevacizumab 21Nivolumab 16Capecitabine 16Irinotecan 15pembrolizumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 10encorafenib 8Folfox protocol 7trifluridine tipiracil drug combination 6Ipilimumab 6Exercise 6fludarabine 5cemiplimab 5Trastuzumab 5Gemcitabine 5Cyclophosphamide 5Cisplatin 5Blood Specimen Collection 5Biopsy 5regorafenib 4pertuzumab 4adagrasib 4Trifluridine 4Surgical Procedures, Operative 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × epigallocatechin gallate × 1 year × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡